Corrigendum: Honokiol ameliorates post-myocardial infarction heart failure through Ucp3-mediated reactive oxygen species inhibition

Front Pharmacol. 2022 Sep 27:13:1000887. doi: 10.3389/fphar.2022.1000887. eCollection 2022.

Authors

Jianyu Liu¹, Minghai Tang¹, Tao Li², Zhengying Su¹, Zejiang Zhu¹, Caixia Dou¹, Yan Liu¹, Heying Pei¹, Jianhong Yang¹, Haoyu Ye¹, Lijuan Chen¹

Affiliations

¹ State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China.
² West China-Washington Mitochondria and Metabolism Center, Department of Anesthesiology, Laboratory of Anesthesiology and Translational Neuroscience Center, West China Hospital of Sichuan University, Chengdu, China.

Abstract

[This corrects the article DOI: 10.3389/fphar.2022.811682.].

Keywords: UCP3; heart failure; honokiol; myocardial infarction; reactive oxygen species.

Copyright © 2022 Liu, Tang, Li, Su, Zhu, Dou, Liu, Pei, Yang, Ye and Chen.

Publication types

Published Erratum